Advertisement

Journal of Radioanalytical and Nuclear Chemistry

, Volume 287, Issue 1, pp 119–127 | Cite as

Preparation and biological evaluation of radiolabeled-folate embedded superparamagnetic nanoparticles in wild-type rats

  • Amir Reza JalilianEmail author
  • Seyyedeh Leila Hosseini-Salekdeh
  • Morteza Mahmoudi
  • Hassan Yousefnia
  • A. Majdabadi
  • Majid Pouladian
Article

Abstract

In this study, superparamagnetic iron oxide nanoparticles (SPION) embedded by folic acid (SPION-folate) were prepared by a modified co-precipitation method. The structure, size, morphology, magnetic property and relaxivity of the SPION-folate were characterized systematically by means of XRD, VSM, HRSEM and TEM and the interaction between folate and iron oxide (Fe3O4) was characterized by FT-IR. The particle size was shown to be ≈5–10 nm. To ensure biocompatibility, the interaction of these SPION with mouse connective tissue cells (adhesive) was investigated using an MTT assay. Consequently, gallium-67 labeled nanoparticles ([67Ga]-SPION-folate) were prepared using 67Ga with a high labeling efficiency (over 96%, RTLC method) and they also showed an excellent stability at room temperature for at least 2 days and were evaluated for their biodistribution in normal rats up to 24 h compared with free Ga3+ cation and [67Ga]-SPION biodistribution. The biodistribution of the tracer among 3 other folate tracers were compared, showing lower liver uptake and higher blood circulation after 24 h leading to better bioavailability. The bone:muscle, kidney:muscle, lung:muscle, stomach:muscle ratios were 9.3, 9.32, 7.6 and 5.83 respectively. The developed folate-containing nano-system can be an interesting folate receptor tracer, capable of better cell membrane permeability while possessing paramagnetic properties for thermotherapy.

Keywords

SPION 67Ga Folate Biodistribution Quality control 

Notes

Acknowledgments

Authors wish to thank Mr S. Daneshvari for conducting animal studies and radioisotope production team at Nuclear Medicine Research Group and Dr. M. A. Rowshanzamir for editorial corrections.

References

  1. 1.
    Mahmoudi M, Simchi A, Milani AS, Stroeve P (2009) J Colloid Interface Sci 336:510CrossRefGoogle Scholar
  2. 2.
    Kamen B (1997) Folate and antifolate pharmacology. Semin Oncol 24(5 Suppl 18):S18–30–9 (PMID 9420019)Google Scholar
  3. 3.
    Campbell IG, Jones TA, Foulkes WD, Trowsdale J (1991) Folate-binding protein is a marker for ovarian cancer. Cancer Res 51(19):5329–5338Google Scholar
  4. 4.
    Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP (2005) Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338(2):284–293CrossRefGoogle Scholar
  5. 5.
    Wu M, Gunning W, Ratnam M (1999) Expression of folate receptor type a in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomark Prev 8:775–783Google Scholar
  6. 6.
    Maziarz KM, Monaco HL, Shen F, Ratnam M (1999) Complete mapping of divergent amino acids responsible for differential ligand binding of folate receptors alpha and beta. J Biol Chem 274(16):11086–11091 (PMID 10196192)CrossRefGoogle Scholar
  7. 7.
    Allard JE, Risinger JI, Morrison C et al (2007) Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. Gynecol Oncol 107(1):52–57. doi: 10.1016/j.ygyno.2007.05.018 (PMID 17582475)CrossRefGoogle Scholar
  8. 8.
    Dainty LA, Risinger JI, Morrison C et al (2007) Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma. Gynecol Oncol 105(3):563–570CrossRefGoogle Scholar
  9. 9.
    Leamon CP (2008) Folate-targeted drug strategies for the treatment of cancer. Curr Opin Investig Drugs 9(12):1277–1286Google Scholar
  10. 10.
    Rossin R, Pan D, Qi MS, Turner JL, Sun X, Wooley KL, Welch MJ (2005) 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J Nucl Med 46:1210–1218Google Scholar
  11. 11.
    Jalilian AR, Panahifar A, Mahmoudi M, Akhlaghi M, Simchi A (2009) Preparation and biological evaluation of [67Ga]-labeled-superparamagnetic nanoparticles in normal rats. Radiochim Acta 97:51–56CrossRefGoogle Scholar
  12. 12.
    Mahmoudi M, Shokrgozar MA, Simchi A, Imani M, Milani AS, Stroeve P, Vali H, Häfeli UO, Sasanpour P, Bonakdar S (2009) Multiphysics flow modeling and in vitro toxicity of iron oxide nanoparticles coated with polyvinyl alcohol. J Phys Chem C 113:2322–2331CrossRefGoogle Scholar
  13. 13.
    Pieters R, Huismans DR, Leyva A, Veerman AJP (1989) Comparison of the rapid automated MTT-assay with a dye exclusion assay for chemosensitivity testing in childhood leukaemia. Br J Cancer 59:217–220Google Scholar
  14. 14.
    Fowlkes WY, Creveling CM (1995) Engineering methods for robust product design: using Taguchi methods in technology and product development. Prentice Hall, New YorkGoogle Scholar
  15. 15.
    Sun Y-K, Ma M, Zhang Y, Gu N (2004) Synthesis of nanometer-size maghemite particles from magnetite. Colloids Surf A: Physicochem Eng Asp 245:15–19CrossRefGoogle Scholar
  16. 16.
    Gracien EB, Ruimin Z, LiHui X, Kanza Kanza L (2006) Effects of pH on the morphology of iron oxides synthesized under gamma-irradiation. J Radioanal Nucl Chem 270:473–478CrossRefGoogle Scholar
  17. 17.
    Zhang X, Zhou R, Rao W (2006) Influence of precipitator agents NaOH and NH4OH on the preparation of Fe3O4 nano-particles synthesized by electron beam irradiation. J Radioanal Nucl Chem 270:285–289CrossRefGoogle Scholar
  18. 18.
    Cornell RM, Schertmann U (1991) Iron oxides in the laboratory: preparation and characterization. VCH, WeinheimGoogle Scholar
  19. 19.
    Chen S, Feng J, Guo X, Hong J, Ding W (2005) One-step wet chemistry for preparation of magnetite nanorods. Mater Lett 59:985–988CrossRefGoogle Scholar
  20. 20.
    Bae DS, Han KS, Cho SB, Choi SH (1998) Synthesis of ultrafine Fe3O4 powder by glycothermal process. Mater Lett 37:255–258CrossRefGoogle Scholar
  21. 21.
    Ma HL, Qia XR (2007) Preparation and characterization of superparamagnetic iron oxide nanoparticles stabilized by alginate. Int J Pharm 333:177–186CrossRefGoogle Scholar
  22. 22.
    Chen Z, Meng H, Yuan H, Xing G, Chen C, Zhao F, Wang Y, Zhang C, Zhao Y (2007) Identification of target organs of copper nanoparticles with ICP-MS technique. J Radioanal Nucl Chem 272(3):599–603CrossRefGoogle Scholar
  23. 23.
    Reddy JA, Xu L-C, Parker N, Vetzel M, Leamon CP (2004) Preclinical evaluation of 99mTc-EC20 for imaging, folate receptor—positive tumors. J Nucl Med 45:857–866Google Scholar
  24. 24.
    M¨uller C, Forrer F, Schibli R, Krenning EP, de Jong M (2008) SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTc-radiofolate. J Nucl Med 49:310–317CrossRefGoogle Scholar
  25. 25.
    Mathias CJ, Wang S, Waters DJ, Turek JJ, Low PS, Mark A (1998) Green indium-111In-DTPA-folate as a potential folate receptor-targeted radiopharmaceutical. J Nucl Med 39:1579–1585Google Scholar
  26. 26.
    Mathias CJ, Wang S, Lee RJ, Waters DJ, Low PS, Mark A (1996) Green tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J Nucl Med 37:1003–1008Google Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2010

Authors and Affiliations

  • Amir Reza Jalilian
    • 1
    Email author
  • Seyyedeh Leila Hosseini-Salekdeh
    • 2
  • Morteza Mahmoudi
    • 3
  • Hassan Yousefnia
    • 1
  • A. Majdabadi
    • 1
  • Majid Pouladian
    • 2
  1. 1.Radiopharmaceutical Research and Development Lab (RRDL)Nuclear Science and Technology Research Institute (NSTRI)TehranIran
  2. 2.Department of Engineering and Technical, Science and Research BranchIslamic Azad UniversityTehranIran
  3. 3.Institute for Nanoscience and NanotechnologySharif University of TechnologyTehranIran

Personalised recommendations